Braeburn Pharmaceuticals
—
by
Braeburn Pharmaceuticals is focused on long-acting treatments in neurological and psychiatric disorders. Probuphine® (buprenorphine) implant for opioid dependence commercially available. Products in development include CAM2038, weekly and monthly subcutaneous injection of buprenorphine, in development for opioid addiction and pain; a risperidone six-month implant and a novel molecule, ATI-9242 for schizophrenia.
Learn more about Braeburn Pharmaceuticals